Kymera Therapeutics, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDKymera Therapeutics, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is moderate (RS Rating: 75), indicating performance broadly in line with the market. Earnings growth of 13% provides fundamental context to the price action. Investors should exercise caution due to high volatility (60% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $80.41 | +12.46% | ABOVE |
| 50 SMA | $83.06 | +8.87% | ABOVE |
| 100 SMA | $82.51 | +9.60% | ABOVE |
| 150 SMA | $79.72 | +13.44% | ABOVE |
| 200 SMA | $73.55 | +22.95% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is KYMR in an uptrend right now?
KYMR has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, KYMR is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is KYMR overbought or oversold?
KYMR's RSI (14) is 66. The stock is in neutral territory, neither overbought nor oversold.
Is KYMR outperforming the market?
KYMR has a Relative Strength (RS) Rating of 75 out of 99. KYMR is performing about average compared to the market.
Where is KYMR in its 52-week range?
KYMR is trading at $90.43, which is 88% of its 52-week high ($103.00) and 81% above its 52-week low ($36.65).
How volatile is KYMR?
KYMR has a Beta of 0.84 and 52-week volatility of 60%. It's less volatile than the S&P 500 - generally more stable.